#### Vanda Pharmaceuticals Inc. Form 3 September 09, 2015 FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB approval OMB approval

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

### OMB 3235-0104 Number: January 31, Expires: 2005

Expires: 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> Reverberi Gian Piero	<ol> <li>Date of Event Requiring Statement (Month/Day/Year)</li> </ol>	3. Issuer Name and Ticker or Trading Symbol Vanda Pharmaceuticals Inc. [VNDA]					
(Last) (First) (Midd	09/08/2015	4. Relationship of Reporting Person(s) to Issuer	ng 5. If Amendment, Date Original Filed(Month/Day/Year)				
2200 PENNSYLVANIA AVENUE, SUITE 300E		(Check all applicabl	Thea(monut Day Tear)				
(Street) WASHINGTON, DC 200	7	Director 100 Officer Off (give title below) (specify b SVP, General Manager I	elow) _X_ Form filed by One Reporting Europe Person Form filed by More than One				
(City) (State) (Zip)	Table I -	Non-Derivative Securi	Reporting Person ties Beneficially Owned				
1.Title of Security (Instr. 4)	2. Amount o Beneficially (Instr. 4)	of Securities 3. Owned Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)				
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)							
information or required to re	respond to the collection of ontained in this form are no spond unless the form disp I OMB control number.	t					
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)							
1. Title of Derivative Security	. Date Exercisable and 3. Title	e and Amount of 4.	5. 6. Nature of Indirect				

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security		4. Conversion or Exercise	5. Ownership Form of	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	(Instr. 4)	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I)	

(Instr. 5)

# **Reporting Owners**

<b>Reporting Owner Name / Address</b>		Relationships					
	Director	10% Owner	Officer	Other			
Reverberi Gian Piero 2200 PENNSYLVANIA AVENU SUITE 300E WASHINGTON, DC 20037	E Â	Â	SVP, General Manager Europe	Â			
Signatures							
/s/ Gian Piero 09/09/ Reverberi	2015						
<u>**</u> Signature of Da Reporting Person	te						

## **Explanation of Responses:**

#### No securities are beneficially owned

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.